Adjuvant chemotherapy of stage I non-small cell lung cancer in North America

被引：4

作者：

Gandara, David R.

Wakelee, Heather

Calhoun, Royce

Jablons, David

机构：

[1] Univ Calif Davis, Ctr Canc, Dept Internal Med, Sacramento, CA 95817 USA

[2] Stanford Univ, Ctr Canc, Palo Alto, CA 94304 USA

[3] Univ Calif San Francisco, Ctr Canc, San Francisco, CA 94143 USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2007年 / 2卷 / 07期

关键词：

D O I：

10.1097/JTO.0b013e318074fe31

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The utility of adjuvant chemotherapy after surgical resection for early-stage non-small cell lung cancer (NSCLC) is now well established. Although a number of randomized clinical trials have demonstrated the efficacy of platinum-based chemotherapy in the overall population treated, subset analysis, excepting Japanese studies, has uniformly shown the greatest efficacy for patients with stage II and III disease and the least benefit for patient with stage I disease. We review data regarding adjuvant therapy of stage I NSCLC from clinical trials performed in North America and Europe. Pertinent trials from Japan are discussed elsewhere in this issue.

引用

页码：S125 / S127

页数：3

共 17 条

[1]

ALBERTI W, 1995, BRIT MED J, V311, P899

[2] Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia [J].

Arteaga, CL .

SEMINARS IN ONCOLOGY, 2002, 29 (05) :3-9

[3]

Douillard JY, 2005, J CLIN ONCOL, V23, p624S

[4] Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J].

Fukuoka, M ;

Yano, S ;

Giaccone, G ;

Tamura, T ;

Nakagawa, K ;

Douillard, JY ;

Nishiwaki, Y ;

Vansteenkiste, J ;

Kudoh, S ;

Rischin, D ;

Eek, R ;

Horai, T ;

Noda, K ;

Takata, I ;

Smit, E ;

Averbuch, S ;

Macleod, A ;

Feyereislova, A ;

Dong, RP ;

Baselga, J .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2237-2246

[5] A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIa non-small-cell lung cancer. [J].

Keller, SM ;

Adak, S ;

Wagner, H ;

Herskovic, A ;

Komaki, R ;

Brooks, BJ ;

Perry, MC ;

Livingston, RB ;

Johnson, DH .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (17) :1217-1222

[6] Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer - A randomized trial [J].

Kris, MG ;

Natale, RB ;

Herbst, RS ;

Lynch, TJ ;

Prager, D ;

Belani, CP ;

Schiller, JH ;

Kelly, K ;

Spiridonidis, H ;

Sandler, A ;

Albain, KS ;

Cella, D ;

Wolf, MK ;

Averbuch, SD ;

Ochs, JJ ;

Kay, AC .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (16) :2149-2158

[7] Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer [J].

Le Chevalier, T ;

Arriagada, R ;

Le Péchoux, C ;

Grunenwald, D ;

Dunant, A ;

Pignon, JP ;

Tarayre, M ;

Abratt, R ;

Arriagada, R ;

Bergman, B ;

Gralla, R ;

Grunenwald, D ;

Le Chevalier, T ;

Orlowski, T ;

Papadakis, E ;

Pinel, MIS ;

Araujo, C ;

Della Torre, H ;

de Solchaga, MM ;

Abdi, E ;

Blum, R ;

Ball, D ;

Basser, R ;

De Boer, R ;

Bishop, J ;

Brigham, B ;

Davis, S ;

Fox, D ;

Richardson, G ;

Wyld, D ;

Pirker, R ;

Humblet, Y ;

Delaunois, L ;

Van Meerbeeck, JP ;

Germonpre, P ;

Vansteenkiste, J ;

Nackaerts, K ;

Pinel, MIS ;

Vauthier, G ;

Younes, RN ;

Arriagada, R ;

Baeza, R ;

Carvajal, P ;

Kleinman, S ;

Orlandi, L ;

Castro, C ;

Godoy, J ;

Kosatova, K ;

Gaafar, R ;

Azarian, R .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (04) :351-360

[8]

PEREZSOLER R, 2001, P AN M AM SOC CLIN, V20, pA310

[9]

Pignon JP, 2006, J CLIN ONCOL, V24, p366S

[10] EPIDERMAL GROWTH FACTOR-RELATED PEPTIDES AND THEIR RECEPTORS IN HUMAN MALIGNANCIES [J].

SALOMON, DS ;

BRANDT, R ;

CIARDIELLO, F ;

NORMANNO, N .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 1995, 19 (03) :183-232

← 1 2 →